Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 29 | 2025 | 167 | 6.780 |
Why?
|
| Anti-HIV Agents | 16 | 2025 | 45 | 4.240 |
Why?
|
| Pre-Exposure Prophylaxis | 15 | 2025 | 43 | 2.990 |
Why?
|
| Contraceptive Devices, Female | 12 | 2025 | 13 | 2.910 |
Why?
|
| HIV-1 | 4 | 2023 | 17 | 1.960 |
Why?
|
| Female | 46 | 2025 | 2964 | 1.650 |
Why?
|
| Humans | 59 | 2025 | 4931 | 1.600 |
Why?
|
| Pyrimidines | 7 | 2025 | 14 | 1.580 |
Why?
|
| Young Adult | 27 | 2025 | 382 | 1.520 |
Why?
|
| Adolescent | 27 | 2025 | 569 | 1.360 |
Why?
|
| Uveitis | 7 | 2019 | 12 | 1.340 |
Why?
|
| Adult | 28 | 2025 | 1402 | 1.200 |
Why?
|
| Drug Overdose | 7 | 2025 | 12 | 1.150 |
Why?
|
| South Africa | 14 | 2025 | 23 | 1.100 |
Why?
|
| Intimate Partner Violence | 6 | 2025 | 6 | 1.090 |
Why?
|
| Surveys and Questionnaires | 8 | 2025 | 179 | 0.820 |
Why?
|
| Male | 27 | 2025 | 2620 | 0.800 |
Why?
|
| Patient Preference | 5 | 2025 | 10 | 0.780 |
Why?
|
| Mycophenolic Acid | 3 | 2016 | 4 | 0.780 |
Why?
|
| Methotrexate | 3 | 2016 | 4 | 0.780 |
Why?
|
| Zimbabwe | 10 | 2025 | 10 | 0.770 |
Why?
|
| Immunosuppressive Agents | 3 | 2016 | 17 | 0.760 |
Why?
|
| Substance Abuse, Intravenous | 4 | 2022 | 10 | 0.740 |
Why?
|
| Antimetabolites | 2 | 2017 | 4 | 0.670 |
Why?
|
| Substance-Related Disorders | 3 | 2025 | 62 | 0.640 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2025 | 50 | 0.610 |
Why?
|
| Cross-Over Studies | 5 | 2024 | 22 | 0.570 |
Why?
|
| Pregnancy | 7 | 2023 | 417 | 0.550 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 21 | 0.520 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2025 | 93 | 0.510 |
Why?
|
| Medication Adherence | 3 | 2025 | 36 | 0.510 |
Why?
|
| Analgesics, Opioid | 3 | 2025 | 49 | 0.460 |
Why?
|
| Opioid-Related Disorders | 2 | 2025 | 12 | 0.450 |
Why?
|
| Middle Aged | 14 | 2025 | 1544 | 0.420 |
Why?
|
| Contraception | 4 | 2022 | 6 | 0.400 |
Why?
|
| Visual Acuity | 5 | 2019 | 62 | 0.370 |
Why?
|
| United States | 8 | 2025 | 764 | 0.330 |
Why?
|
| Choice Behavior | 4 | 2025 | 8 | 0.330 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 2 | 2020 | 3 | 0.320 |
Why?
|
| Patient Compliance | 2 | 2020 | 30 | 0.320 |
Why?
|
| Uganda | 6 | 2025 | 6 | 0.320 |
Why?
|
| Tenofovir | 3 | 2025 | 8 | 0.310 |
Why?
|
| Social Stigma | 2 | 2025 | 15 | 0.300 |
Why?
|
| Kenya | 6 | 2025 | 7 | 0.290 |
Why?
|
| Vaccination | 2 | 2025 | 34 | 0.280 |
Why?
|
| Panuveitis | 2 | 2017 | 2 | 0.270 |
Why?
|
| Fentanyl | 2 | 2023 | 7 | 0.260 |
Why?
|
| Quality of Life | 2 | 2019 | 139 | 0.260 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 54 | 0.250 |
Why?
|
| Qualitative Research | 2 | 2023 | 44 | 0.250 |
Why?
|
| Drug Users | 2 | 2024 | 3 | 0.250 |
Why?
|
| Disease Transmission, Infectious | 1 | 2025 | 5 | 0.240 |
Why?
|
| Peer Group | 1 | 2025 | 12 | 0.240 |
Why?
|
| Bullying | 1 | 2025 | 5 | 0.240 |
Why?
|
| Chemoprevention | 1 | 2025 | 9 | 0.240 |
Why?
|
| Indians, North American | 1 | 2025 | 2 | 0.240 |
Why?
|
| Crime Victims | 1 | 2025 | 10 | 0.240 |
Why?
|
| Gender-Based Violence | 1 | 2025 | 2 | 0.240 |
Why?
|
| Sex Offenses | 1 | 2025 | 4 | 0.240 |
Why?
|
| Ecological Momentary Assessment | 1 | 2025 | 1 | 0.240 |
Why?
|
| Schools | 2 | 2025 | 14 | 0.230 |
Why?
|
| Criminal Law | 1 | 2024 | 3 | 0.230 |
Why?
|
| Law Enforcement | 1 | 2024 | 4 | 0.230 |
Why?
|
| Needle-Exchange Programs | 2 | 2021 | 2 | 0.230 |
Why?
|
| Administration, Oral | 5 | 2025 | 36 | 0.220 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 124 | 0.220 |
Why?
|
| Smoking | 3 | 2023 | 59 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 5 | 0.210 |
Why?
|
| Contraceptive Agents | 1 | 2023 | 2 | 0.210 |
Why?
|
| Insurance, Health | 1 | 2023 | 23 | 0.200 |
Why?
|
| Alcohol Drinking | 1 | 2023 | 39 | 0.200 |
Why?
|
| Domestic Violence | 1 | 2022 | 1 | 0.200 |
Why?
|
| Soft Tissue Infections | 1 | 2022 | 3 | 0.190 |
Why?
|
| Health Promotion | 1 | 2022 | 70 | 0.190 |
Why?
|
| Adolescent Behavior | 1 | 2022 | 19 | 0.190 |
Why?
|
| Sexual Behavior | 1 | 2022 | 49 | 0.190 |
Why?
|
| Drug Implants | 1 | 2021 | 7 | 0.180 |
Why?
|
| Residence Characteristics | 4 | 2022 | 27 | 0.180 |
Why?
|
| Risk Factors | 5 | 2025 | 593 | 0.180 |
Why?
|
| California | 4 | 2025 | 161 | 0.180 |
Why?
|
| Crime | 1 | 2021 | 5 | 0.180 |
Why?
|
| Longitudinal Studies | 3 | 2025 | 92 | 0.170 |
Why?
|
| Health Status | 2 | 2019 | 61 | 0.170 |
Why?
|
| Vagina | 1 | 2020 | 13 | 0.170 |
Why?
|
| Menstruation | 1 | 2020 | 3 | 0.170 |
Why?
|
| Hygiene | 1 | 2020 | 2 | 0.170 |
Why?
|
| Depression | 1 | 2021 | 97 | 0.160 |
Why?
|
| Sickness Impact Profile | 1 | 2019 | 6 | 0.160 |
Why?
|
| Anxiety | 1 | 2019 | 32 | 0.160 |
Why?
|
| San Francisco | 3 | 2023 | 10 | 0.150 |
Why?
|
| Heroin Dependence | 1 | 2018 | 3 | 0.150 |
Why?
|
| Binge Drinking | 1 | 2018 | 4 | 0.150 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2018 | 4 | 0.150 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 9 | 0.150 |
Why?
|
| Fluprednisolone | 1 | 2018 | 1 | 0.150 |
Why?
|
| Georgia | 3 | 2025 | 4 | 0.150 |
Why?
|
| North Carolina | 3 | 2025 | 4 | 0.150 |
Why?
|
| Administration, Intravaginal | 3 | 2024 | 4 | 0.150 |
Why?
|
| Macula Lutea | 1 | 2018 | 5 | 0.150 |
Why?
|
| Research Subjects | 1 | 2018 | 6 | 0.150 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 358 | 0.140 |
Why?
|
| Sarcoidosis | 1 | 2017 | 3 | 0.140 |
Why?
|
| Uveitis, Posterior | 1 | 2017 | 1 | 0.140 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 202 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2022 | 229 | 0.140 |
Why?
|
| Bayes Theorem | 1 | 2016 | 21 | 0.130 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2016 | 1 | 0.130 |
Why?
|
| Scleritis | 1 | 2016 | 1 | 0.130 |
Why?
|
| Eye Infections, Viral | 1 | 2016 | 1 | 0.130 |
Why?
|
| Uveomeningoencephalitic Syndrome | 1 | 2016 | 1 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 35 | 0.130 |
Why?
|
| Registries | 1 | 2016 | 53 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2018 | 513 | 0.110 |
Why?
|
| Alabama | 2 | 2025 | 5 | 0.110 |
Why?
|
| Naloxone | 2 | 2024 | 17 | 0.110 |
Why?
|
| Narcotic Antagonists | 2 | 2024 | 26 | 0.110 |
Why?
|
| Africa South of the Sahara | 2 | 2025 | 18 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2025 | 53 | 0.100 |
Why?
|
| Homosexuality, Male | 2 | 2025 | 41 | 0.100 |
Why?
|
| Social Environment | 2 | 2022 | 12 | 0.100 |
Why?
|
| Pregnancy, Unplanned | 2 | 2022 | 2 | 0.100 |
Why?
|
| Counseling | 2 | 2022 | 11 | 0.100 |
Why?
|
| Syringes | 2 | 2022 | 4 | 0.090 |
Why?
|
| Child | 2 | 2025 | 336 | 0.090 |
Why?
|
| Economics, Behavioral | 2 | 2023 | 2 | 0.090 |
Why?
|
| India | 2 | 2023 | 10 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 83 | 0.090 |
Why?
|
| Demography | 2 | 2023 | 19 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2022 | 224 | 0.090 |
Why?
|
| Aged | 3 | 2018 | 1188 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 126 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2018 | 70 | 0.070 |
Why?
|
| Macular Edema | 2 | 2018 | 7 | 0.060 |
Why?
|
| Logistic Models | 2 | 2018 | 117 | 0.060 |
Why?
|
| Hawaii | 2 | 2016 | 5 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2018 | 402 | 0.060 |
Why?
|
| Sexual Harassment | 1 | 2025 | 1 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2025 | 31 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 58 | 0.060 |
Why?
|
| Oregon | 1 | 2024 | 1 | 0.060 |
Why?
|
| Focus Groups | 1 | 2024 | 33 | 0.060 |
Why?
|
| Emtricitabine | 1 | 2024 | 5 | 0.060 |
Why?
|
| Prevalence | 1 | 2025 | 184 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2024 | 22 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 7 | 0.050 |
Why?
|
| Health Education | 1 | 2024 | 46 | 0.050 |
Why?
|
| Tobacco Products | 1 | 2023 | 8 | 0.050 |
Why?
|
| HIV | 1 | 2023 | 5 | 0.050 |
Why?
|
| Mental Health | 1 | 2023 | 40 | 0.050 |
Why?
|
| Trust | 1 | 2022 | 10 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 45 | 0.050 |
Why?
|
| Family Planning Services | 1 | 2022 | 2 | 0.050 |
Why?
|
| Decision Making | 1 | 2022 | 17 | 0.050 |
Why?
|
| Needle Sharing | 1 | 2022 | 1 | 0.050 |
Why?
|
| Coitus | 1 | 2022 | 7 | 0.050 |
Why?
|
| Disclosure | 1 | 2021 | 2 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2021 | 4 | 0.050 |
Why?
|
| Data Collection | 1 | 2021 | 27 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 1 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 106 | 0.040 |
Why?
|
| Malawi | 1 | 2020 | 2 | 0.040 |
Why?
|
| Clinical Studies as Topic | 1 | 2019 | 1 | 0.040 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 20 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 2 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 8 | 0.040 |
Why?
|
| Consumer Behavior | 1 | 2019 | 2 | 0.040 |
Why?
|
| Placebos | 1 | 2019 | 8 | 0.040 |
Why?
|
| Injections | 1 | 2019 | 13 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 81 | 0.040 |
Why?
|
| Health Surveys | 1 | 2019 | 55 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2019 | 42 | 0.040 |
Why?
|
| Injection Site Reaction | 1 | 2018 | 1 | 0.040 |
Why?
|
| Crack Cocaine | 1 | 2018 | 3 | 0.040 |
Why?
|
| Methamphetamine | 1 | 2018 | 4 | 0.040 |
Why?
|
| Sex Work | 1 | 2018 | 7 | 0.040 |
Why?
|
| Health Services | 1 | 2018 | 11 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2018 | 13 | 0.040 |
Why?
|
| Unsafe Sex | 1 | 2018 | 9 | 0.040 |
Why?
|
| Ophthalmic Solutions | 1 | 2018 | 12 | 0.040 |
Why?
|
| Maryland | 1 | 2018 | 1 | 0.040 |
Why?
|
| Pennsylvania | 1 | 2018 | 3 | 0.040 |
Why?
|
| Colorado | 1 | 2018 | 3 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2018 | 43 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2018 | 9 | 0.040 |
Why?
|
| Condoms | 1 | 2018 | 14 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2018 | 34 | 0.040 |
Why?
|
| Income | 1 | 2018 | 20 | 0.040 |
Why?
|
| Comorbidity | 1 | 2018 | 123 | 0.040 |
Why?
|
| Biopsy | 1 | 2017 | 23 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2018 | 177 | 0.030 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 23 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 45 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 43 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 245 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 33 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 35 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 40 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 141 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 6 | 0.030 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 6 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 67 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 60 | 0.030 |
Why?
|